Showing 5091-5100 of 10104 results for "".
- Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Wartshttps://practicaldermatology.com/news/positive-results-for-aclaris-therapeutics-a-101-45-topical-solution-in-pivotal-phase-3-trial-for-the-treatment-of-warts/2460151/Aclaris Therapeutics, Inc., shared positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution, an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the
- Study: Long-Term Use of Brodalumab Is Safe, Effectivehttps://practicaldermatology.com/news/study-long-term-use-of-brodalumab-is-safe-effective/2460150/Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology. Ov
- ASDS 2018 Survey: Skin Cancer Treatments and Cosmetic Procedures are on the Risehttps://practicaldermatology.com/news/asds-2018-survey-skin-cancer-treatments-and-cosmetic-procedures-are-on-the-rise/2460133/American Society for Dermatologic Surgery (ASDS) member dermatologists performed more than 12.5 million medical and cosmetic procedures in 2018 – 7.5 percent more than 2017 and a 60 percent increase since 2012, according to the 2018 ASDS
- Cassiopea Submits NDA for New Acne Treatmenthttps://practicaldermatology.com/news/cassiopea-submits-nda-for-new-acne-treatment/2460131/Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne. Clascoterone cream 1% is under investigation as a first-in-class topical androgen receptor inhibitor for th
- Blocking LSD1 May Thwart Common Skin Cancer Growthhttps://practicaldermatology.com/news/blocking-lsd1-may-thwart-common-skin-cancer-growth/2460130/The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow. A new study from researchers in the Perelman School of Medicine at the University of Pennsylvania has now identifie
- Study Shows StrataGraft-treated Deep Partial-thickness Burns Did Not Require Surgical Harvest of Healthy Skinhttps://practicaldermatology.com/news/study-shows-stratagraft-treated-deep-partial-thickness-burns-did-not-require-surgical-harvest-of-healthy-skin/2460127/Mallinckrodt plc shared results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries (ISBI). Study data showed that treatment with a single application of StrataGraft tissue resulted in
- Complete Wound Healing Seen on Index Lesion of the First Subject in an Ongoing Phase 2 Trial of RGN-137 Dermal Gel for EBhttps://practicaldermatology.com/news/complete-wound-healing-seen-on-index-lesion-of-the-first-subject-in-an-ongoing-phase-2-trial-of-rgn-137-dermal-gel-for-eb/2460118/Lenus Therapeutics, LLC, a US-based joint venture between GtreeBNT and Yuyang DNU in Korea, has confirmed complete wound healing of the index lesion of the first subject enrolled in its ongoing single-masked Phase 2 clinical trial with RGN-137 dermal gel for Epidermolysis Bullosa (EB).
- Foamix Submits NDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosaceahttps://practicaldermatology.com/news/foamix-submits-nda-for-fmx103-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea/2460117/Foamix Pharmaceuticals Ltd. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older
- Summer AAD News: Dramatic Spike in Female Skin Cancer Linked to Tanninghttps://practicaldermatology.com/news/summer-aad-news-dramatic-spike-in-female-skin-cancer-linked-to-tanning/2460105/Skin cancer in women is on the rise, and indoor tanning may be to blame, according to new research presented at the 2019 American Academy of Dermatology Summer Meeting in New York City. Between 1970 and 2009, rates of melanoma increased 800 percent among women ages 18-39, making it the
- Proof of Concept Study Supports Dermata’s Topical Delivery Mechanism for Botulinum Toxinhttps://practicaldermatology.com/news/proof-of-concept-study-supports-dermatas-topical-delivery-mechanism-for-botulinum-toxin/2460089/Dermata Therapeutics’ DMT410 (DMT310 + botulinum toxin) performed well in a Phase 1proof of concept study for the treatment of primary axillary hyperhidrosis, the Company reports. DMT410 is a combination regimen for the treatment of skin